Our Unfair Advantage

NeurotechMag Pro (opens in a new window) tracks funding rounds, neural device trials, FDA clearances, regulatory catalysts, and leadership moves across the global neurotechnology sector as they happen. That means we often know a company is fundable before it starts fundraising, and we’re rarely working from the same deal flow everyone else sees.

Live and already built — not a future concept. Overseen by the General Partner, Europe’s global market intelligence function.